Multiple sclerosis health-related quality of life utility values from the UK MS register.

IF 2.5 Q2 CLINICAL NEUROLOGY
A Heather, E Goodwin, C Green, N Morrish, O C Ukoumunne, R M Middleton, A Hawton
{"title":"Multiple sclerosis health-related quality of life utility values from the UK MS register.","authors":"A Heather,&nbsp;E Goodwin,&nbsp;C Green,&nbsp;N Morrish,&nbsp;O C Ukoumunne,&nbsp;R M Middleton,&nbsp;A Hawton","doi":"10.1177/20552173231178441","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>New interventions for multiple sclerosis (MS) commonly require a demonstration of cost-effectiveness using health-related quality of life (HRQoL) utility values. The EQ-5D is the utility measure approved for use in the UK NHS funding decision-making. There are also MS-specific utility measures - e.g., MS Impact Scale Eight Dimensions (MSIS-8D) and MSIS-8D-Patient (MSIS-8D-P).</p><p><strong>Objectives: </strong>Provide EQ-5D, MSIS-8D and MSIS-8D-P utility values from a large UK MS cohort and investigate their association with demographic/clinical characteristics.</p><p><strong>Methods: </strong>UK MS Register data from 14,385 respondents (2011 to 2019) were analysed descriptively and using multivariable linear regression, with self-report Expanded Disability Status Scale (EDSS) scores.</p><p><strong>Results: </strong>The EQ-5D and MSIS-8D were both sensitive to differences in demographic/clinical characteristics. An inconsistency found in previous studies whereby mean EQ-5D values were higher for an EDSS score of 4 rather than 3 was not observed. Similar utility values were observed between MS types at each EDSS score. Regression showed EDSS score and age were associated with utility values from all three measures.</p><p><strong>Conclusions: </strong>This study provides generic and MS-specific utility values for a large UK MS sample, with the potential for use in cost-effectiveness analyses of treatments for MS.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"9 2","pages":"20552173231178441"},"PeriodicalIF":2.5000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265354/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20552173231178441","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: New interventions for multiple sclerosis (MS) commonly require a demonstration of cost-effectiveness using health-related quality of life (HRQoL) utility values. The EQ-5D is the utility measure approved for use in the UK NHS funding decision-making. There are also MS-specific utility measures - e.g., MS Impact Scale Eight Dimensions (MSIS-8D) and MSIS-8D-Patient (MSIS-8D-P).

Objectives: Provide EQ-5D, MSIS-8D and MSIS-8D-P utility values from a large UK MS cohort and investigate their association with demographic/clinical characteristics.

Methods: UK MS Register data from 14,385 respondents (2011 to 2019) were analysed descriptively and using multivariable linear regression, with self-report Expanded Disability Status Scale (EDSS) scores.

Results: The EQ-5D and MSIS-8D were both sensitive to differences in demographic/clinical characteristics. An inconsistency found in previous studies whereby mean EQ-5D values were higher for an EDSS score of 4 rather than 3 was not observed. Similar utility values were observed between MS types at each EDSS score. Regression showed EDSS score and age were associated with utility values from all three measures.

Conclusions: This study provides generic and MS-specific utility values for a large UK MS sample, with the potential for use in cost-effectiveness analyses of treatments for MS.

Abstract Image

Abstract Image

Abstract Image

来自英国多发性硬化症登记册的多发性硬化症与健康相关的生活质量效用值。
背景:多发性硬化症(MS)的新干预措施通常需要使用与健康相关的生活质量(HRQoL)效用值来证明成本效益。EQ-5D是批准用于英国国民保健服务资助决策的实用措施。还有MS特定的效用测量-例如,MS影响量表八维度(MSIS-8D)和MSIS-8D-患者(MSIS-8D- p)。目的:从英国一个大型MS队列中提供EQ-5D、MSIS-8D和MSIS-8D- p的效用值,并调查它们与人口统计学/临床特征的关系。方法:采用多变量线性回归和自我报告的扩展残疾状态量表(EDSS)评分,对2011年至2019年14385名受访者的英国MS Register数据进行描述性分析。结果:EQ-5D和MSIS-8D对人口统计学/临床特征的差异都很敏感。在先前的研究中没有发现不一致的现象,即EDSS评分为4而不是3的平均EQ-5D值更高。在每个EDSS评分中,MS类型之间观察到相似的效用值。回归显示EDSS评分和年龄与所有三项测量的效用值相关。结论:该研究为英国大型多发性硬化症样本提供了通用和多发性硬化症特异性实用价值,具有用于多发性硬化症治疗的成本效益分析的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
0.00%
发文量
54
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信